Trial Profile
Safety and Efficacy of Escalating Doses of Ingenol Mebutate Once Daily for Two or Three Consecutive Days When Used on Full Face, Full Balding Scalp or Approximately 250 cm2 on the Chest in Subjects With Actinic Keratosis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 May 2021
Price :
$35
*
At a glance
- Drugs Ingenol mebutate (Primary)
- Indications Actinic keratosis; Skin cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors LEO Pharma
- 08 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Apr 2014 New source identified and integrated (Oregon Health and Science University Institutional Review Board; IRB00010106)
- 05 Apr 2013 New trial record